Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors()

PURPOSE: Advanced NSCLC harboring epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) typically progresses after initial response due to acquired resistance. TKIs are often continued beyond progressive disease by RECIST. We investigated the practice...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nishino, Mizuki, Cardarella, Stephanie, Dahlberg, Suzanne E., Jackman, David M., Ramaiya, Nikhil H., Hatabu, Hiroto, Rabin, Michael S., Jänne, Pasi A., Johnson, Bruce E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3580850/
https://ncbi.nlm.nih.gov/pubmed/23254265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2012.11.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados